Prediction of ECT Treatment Response and Reduction of Cognitive Side-effects Using EEG and Rivastigmine

NCT05768126 · clinicaltrials.gov ↗

PHASE4

Phase

RECRUITING

Status

100

Enrollment

OTHER

Sponsor class

Conditions

Depressive Disorder

Interventions

DRUG: Rivastigmine Transdermal Product
OTHER: Sham

Sponsor

UMC Utrecht

Collaborators

[object Object]
[object Object]
[object Object]